Adding Finerenone to SGLT2 Inhibitors and Long-Term Kidney Outcomes in Diabetic Kidney Disease
Adding a fourth blood pressure drug to standard kidney-disease therapy significantly slows kidney decline in diabetic patients.
In 255 DKD patients on RASi+SGLT2i, adding finerenone (triple combination) versus continuing dual therapy was associated with significantly greater proteinuria reduction (47% at 24 months) and a meaningful improvement in long-term eGFR slope after PS matching. The findings support triple combination therapy as an additional renoprotective strategy in DKD, complementing existing evidence from the FIDELIO-DKD and FIGARO-DKD trials.
What the study was
- Study design
- Retrospective cohort with propensity score matching (intention-to-treat)
- Population
- DKD patients on combined RASi + SGLT2i therapy at two centers in Japan; triple therapy (n~127) vs dual therapy (n~128 after PS matching)
- Sample size
- 255
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes Obes Metab
Why it surfaced
Real-world evidence supporting triple combination (finerenone+RASi+SGLT2i) as a renoprotective strategy in DKD; fills a gap not directly addressed by pivotal RCTs; clinically applicable now pending guideline uptake.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.